STOCK TITAN

Glaukos Corporation - GKOS STOCK NEWS

Welcome to our dedicated news page for Glaukos Corporation (Ticker: GKOS), a resource for investors and traders seeking the latest updates and insights on Glaukos Corporation.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Glaukos Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Glaukos Corporation's position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.64%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
earnings
Glaukos Corporation

NYSE:GKOS

GKOS Rankings

GKOS Stock Data

4.59B
47.49M
3.92%
104.92%
7.46%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
San Clemente

About GKOS

glaukos corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. glaukos has pioneered micro-invasive glaucoma surgery, or migs, to revolutionize the traditional glaucoma treatment and management paradigm. the company launched the istent trabecular micro-bypass stent, its first migs device, in the united states in 2012. glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. glaukos believes the istent is the smallest medical device ever approved by the food and drug administration, or fda, measuring 1.0 mm long and 0.33 mm wide. in june 2015, the company completed an initial public offering and its shares are now traded on the new york stock exchange unde